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Two HIV-1 proteins, Tat and NCp7 (NC), have zinc finger-like structures. NC is a virion protein and has been shown to
accumulate in the nucleus 8 h postinfection. Since transcription factors with zinc fingers assist the transcriptional activity of
both RNA polymerases II and III, we examined the effect of NC on HIV-1 LTR-directed gene expression. The HIV-1 NC binds
to the HIV-1 LTR and results in a mobility shift in polyacrylamide gel electrophoresis. Competition assays with cold probes
revealed that the binding of NC and formation of a DNA–protein complex could be prevented by the addition of excess
unlabeled LTR self-probe, but not the HIV-1 V3 envelope gene. The DNase I footprint analysis showed that NC binds to six
regions within HIV-1 LTR, four of which are near the transcription start site. The NC alone enhances LTR basal-level activity
in RNA runoff experiments. When the general transcription factors (GTFs) were added in the assay, NC enhances NF-kB, Sp1,
and TFIIB-induced HIV-1 LTR-directed RNA transcription. RNA transcription directed by the adenovirus major late promoter,
however, is not significantly affected by NC in the cell-free system. Transient transfection of human T lymphocytes with the
plasmids containing HIV-1 nc or gag showed enhancement of LTR-CAT activity. Moreover, transfection of HIV-1 provirus
containing mutations in NC zinc-finger domains dramatically decreases the enhancement activity in human T cells, in which
HIV-1 LTR is stably integrated into the cellular genome. These observations show that NC binds to HIV-1 LTR and
cooperatively enhances GTFs and NF-kB induced HIV-1 LTR basal-level activity. NC may play the role of a nucleation protein,
which binds to LTR and enhances basal-level transcription by recruiting cellular transcription factors to the HIV-1 promoter
in competition with cellular promoters. © 2000 Academic PressKey Words: HIV-1; nucleocapsid protein; DNA binding protein; footprint; enhancement.INTRODUCTION
HIV-1 has two proteins with zinc finger-like structures,
Tat and NCp7 (Sen and Todaro, 1977; Berg, 1986; Frankel
et al., 1988; Green and Berg, 1989; South et al., 1990;
arlix et al., 1995; Coffin, 1996; Luciw, 1996). Tat is an
mportant transcription factor in HIV-1 RNA expression.
IV-1 NCp7 (NC), a virion protein, migrates from cyto-
lasm to nucleus and accumulates in the nucleus 8 h
ostinfection (Gallay et al., 1995). NC enters the nucleus
y association with HIV-1 preintegration complex (Darlix
t al., 1990; Luban and Goff, 1991; Sharova et al., 1991;
erkowitz et al., 1993; Lapadat-Tapolsky et al., 1993;
Geigenmuller and Linial, 1996; Miller et al., 1997;
Schwartz et al., 1997). In comparison with Tat, NC con-
tains two classic zinc-finger DNA binding motifs, which
are found in authentic transcription factors (Miller et al.,
1985; Kadonaga et al., 1987; Evans and Hollenberg, 1988;
Levine and Hoey, 1988), providing a prima facie case for
investigating a possible role for NC as a transcription
factor in HIV-1 replication.
Part of the data from this study was presented at Cold Spring Harbor,
NY, Meeting on Retroviruses, May 25–30, 1999.
1 To whom correspondence and reprint requests should be ad-
dressed at Beth Israel Deaconess Medical Center, Division of Infec-
tious Diseases, Dana 617, 330 Brookline Avenue, Boston, MA 02215.
Fax: (617) 667-5541. E-mail: lzhang@caregroup.harvard.edu.
251In the HIV-1 replication cycle, Tat acts as an important
transcription regulator and dramatically increases HIV-1
RNA expression from a basal level to the “Tat-induced
level” (Feinberg et al., 1991; Kessler and Mathews, 1991;
Cullen, 1993; Lu et al., 1993; Adams et al., 1994; Moses et
al., 1994). As an important transcription factor, Tat does
not regulate HIV-1 LTR activity from the beginning of viral
infection. Tat is not a virion protein but is synthesized
after HIV-1 enters cells (Coffin, 1996; Luciw, 1996). Tat
mRNA and TAR element are transcribed by LTR basal-
level activity (Feinberg et al., 1991; Kessler and Mathews,
1991; Cullen, 1993; Adams et al., 1994; Michael et al.,
1994; Moses et al., 1994; Alcami et al., 1995; Xiao et al.,
1997). In a sense, HIV-1 LTR basal-level activity is a
prerequisite for Tat-induced HIV-1 replication.
A virion-associated protein that would regulate HIV-1
LTR basal-level activity has been studied by others.
Huang et al. (1994) showed that tat (2) viruses were fully
competent for viral gene expression, based on the as-
sessments of viral protein synthesis and virion assembly.
They suggested that this tat (2) LTR-directed gene ex-
pression might emanate from virion-associated Tat pro-
tein. Fridell et al. (1995) have reported that a human
zinc-finger protein may play a role in mediating the bio-
logical activity of the HIV-1 Tat by specifically interacting
with the activation domain of Tat. Our current study
suggests that viral NC protein plays a role in regulating
0042-6822/00 $35.00
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252 ZHANG, SHARMA, AND CRUMPACKERHIV-1 LTR basal-level activity. Based on previous docu-
mentation (Sen and Todaro, 1977; Berg, 1986; Darlix et
al., 1990; South et al., 1990; Luban and Goff, 1991; Sha-
ova et al., 1991; Berkowitz et al., 1993; Lapadat-Tapolsky
t al., 1993; Darlix et al., 1995; Geigenmuller and Linial,
996; Miller et al., 1997; Schwartz et al., 1997), we rec-
gnized that a viral protein possessing a zinc-finger DNA
inding motif and entering the nucleus in the early phase
f infection might have an ability to regulate viral gene
xpression. Previous studies have shown that HIV-1 rep-
icates vigorously in vivo without a latent phase (Gendel-
an et al., 1989; Mellors et al., 1991; Pantaleo et al.,
993a,b; Coffin, 1995; Ho et al., 1995; Wei et al., 1995;
erelson et al., 1996). Tat can increase HIV-1 replication
ore than 30,000-fold in vitro. HIV-1 LTR basal-level
ctivity, however, appears to be totally controlled by the
ctivity of cellular factors. Since HIV-1 can replicate in
ondividing cells, HIV-1 may also regulate basal-level
ctivity by its own proteins, rather than limiting its repli-
ation before Tat is translated.
Similar to other retroviruses, HIV-1 initiates its replica-
ion by manipulating cellular transcriptional machinery to
ranscribe the HIV-1 early mRNA. This process seems to
e highly regulated and is difficult to explain simply by
ellular general transcriptional factors (GTFs) binding on
he HIV-1 LTR randomly and pre-Tat viral mRNAs tran-
cribed by chance. HIV-1 may be able to use an inter-
ediary protein, which not only binds to LTR with high
ffinity but also enhances the recruitment of GTFs to the
iral promoter rather than to the cellular promoters. NC
ay play such a role. To test this hypothesis, we first
xamined the DNA binding ability of NC in gel mobility-
hift assay, and found the binding region of NC within
TR by footprinting analysis. Next, we determined the
ffect of NC on inducing HIV-1 LTR basal-level activity in
itro using RNA runoff experiments. Finally, we examined
he activity of NC on LTR-directed gene expression in
ransiently transfected T lymphocytes. Our data show
hat HIV-1 NC binds to the HIV-1 LTR and enhances LTR
asal-level activity in cooperation with cellular-transcrip-
ion factors. NC also enhances LTR-CAT activity post-
ransfection in T lymphocytes. These results suggest that
IV-1 uses NC initially to upregulate LTR basal-level
ctivity. This regulation precedes the high-level expres-
ion of HIV-1 RNA induced by Tat.
RESULTS
C binding to HIV-1 LTR and resulting in band shift
n the gel
To determine whether NC can play a role in regulating
TR activity, we first examined the ability of NC to bind to
he HIV-1 promoter with mobility-shift assays and DNase
footprinting analysis.
NC binds to both LTR probes 1 and 2, and causes a
obility shift of the band on the gel (Fig. 1). The binding
f NC to LTR was independent of the presence of nuclear Nxtract in the binding reaction. However, the presence of
uclear extract appears to enhance the band retardation
n the gel. Using the same experimental system, we
ested whether other Gag proteins also bind to HIV-1
TR. HIV-1 Gag p24, however, did not result in a mobility
hift on the gel (data not shown), indicating p24 does not
ind to the HIV-1 LTR under these assay conditions.
To further examine the feature of NC binding to HIV-1
TR, we performed a two-way competitive binding assay.
his assay was performed according to the principle of a
and-shift assay, previously used by others in studying
inc-finger proteins (Hardy and Shenk, 1988; Chang et al.,
989; Shi et al., 1991). Both HIV-1 LTR and V3 DNA were
ested as the labeled probes as well as the cold com-
etitors. If NC binds to HIV-1 LTR with higher affinity, the
TR sequences will compete for V3 sequences, binding
uch more effectively than V3 sequences will compete
or LTR binding. The two-way competition assay showed
hat NC binds to HIV-1 LTR with higher affinity than to V3
equences (Figs. 2a and 2b). NC binds to LTR and
auses a band shift, even if V3 sequences are present in
,000-fold molar excess of the labeled LTR (Fig. 2a). In
ontrast, the V3 DNA failed to compete with LTR in
inding to NC (Fig. 2b). NC binding to V3 sequences was
ompeted out by cold LTR, and the released V3 probe
ormed bands at the position equivalent to the band of
robe only (Fig. 2b, lanes 1 and 3–5). NC can cause
ome level of gel retardation of V3 DNA when LTR is not
resent as a competitor (Fig. 2b, lane 2). These results of
he band-shift assay suggested that NC may bind to
IV-1 LTR in a sequence-specific manner.
We further examined NC binding of LTR by using the
old self-probe as a competitor. Three different concen-
rations of cold probes were added to competitively bind
32 32
FIG. 1. HIV-1 NC binding to the HIV-1 LTR promoter by gel mobility-
shift analysis. The [a-32P]dCTP-labeled probes 1 and 2 are double-
tranded HIV-1 59 LTR fragments extending from bp 2416 to 2112 and
2134 to 1155. The binding condition is as described under Materials
and Methods. Probes 1 and 2 were incubated with 1 mg of NC (lanes
and 5), with 1 mg of NC and 10 mg of nuclear protein prepared from
CPT-K5 cells (lanes 2 and 6), with 10 mg of nuclear protein (lanes 3 and
), or in the absence of NC and nuclear protein (lanes 4 and 8). Data
how that NC binds to the HIV-1 LTR promoter, inducing a mobility shift
n the gel.C with the [a- P]-labeled probes. The [a- P]-labeled
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253ENHANCING HIV-1 LTR BASAL-LEVEL ACTIVITY BY HIV-1 NCp7probes are displaced after the self-competitors (cold
probe 2) are added (Fig. 3, lanes 3–5). The displaced
radiolabeled probes form a band at the position of
probes only (Fig. 3, lane 1) and the band shift is inhibited
in a competitor concentration-dependent manner. The
cold probes HIV-1 V3 and human b-globin DNA were
xamined in the same experiment, and both V3 and
b-globin DNA failed to compete with LTR in binding to
NC, even at the concentration which is 1,000-fold of
molar excess the hot probe (Fig. 3, lanes 6–9). These
results show that NC binds to LTR with much higher
affinity than it binds to other DNA.
NC binding to multiple regions within HIV-1 LTR
The binding regions of NC on HIV-1 LTR was exam-
FIG. 2. Two-way competition analysis of HIV-1 NC binding to the
IV-1 promoter. (a) HIV-1 LTR fragment 2 serves as the labeled probe
nd cold V3 fragment as the competitor. The labeled double-stranded
IV-1 LTR probe 2 was incubated without NC (lane 1), with 0.75 mg of
C (lane 2), with 0.75 mg of NC, and the unlabeled V3 fragment at a
300-, 900-, and 2,700-fold molar excess over labeled LTR probe (lanes
3–5). Data show that V3 fails to outcompete labeled LTR probe for
binding NC. (b) HIV-1 V3 fragment serves as the labeled probe and cold
LTR fragment 2 as the competitor. The labeled double-stranded HIV-1
V3 probe was incubated without NC (lane 1), with 0.75 mg of NC (lane
), with 0.75 mg of NC, and the unlabeled LTR fragment (probe 2) at a
00-, 900-, and 2,700-fold molar excess over labeled V3 probe (lanes
–5). Data show that LTR outcompetes labeled V3 for binding NC in a
oncentration dependent manner.ined with footprint analysis. DNase I footprint experi- Hments revealed that NC binds to six regions within HIV-1
LTR. Both of the HIV-1 LTR probes were examined, ex-
tending from bp 2416 to 1155, which takes into account
the entire 59 LTR of HIV-1. In the six NC binding regions,
regions one and two were located near the 39 of probe 1,
nd four other regions were in a cluster near the center
f probe 2 (Figs. 4a and 4b). Various concentrations
0.4–4 mg) of NC were used in footprinting analysis, and
the binding region extends when the concentration of NC
increases. The gels show bands of unprotected DNA at
all concentrations of NC, indicating that binding is spe-
cific. The nucleotide sequences of these binding regions
on 59 HIV-1 LTR are shown in Fig. 4c.
The band-shift assay showed that NC binds to HIV-1
LTR with affinity, and the footprinting assay further
showed that NC binds to six regions with LTR. These
results provide biochemical evidence to suggest that NC
may regulate HIV-1 promoter basal-level activity to ben-
efit HIV-1 replication. As shown in Fig. 1, NC binds to both
LTR probes and causes the mobility shifts in the gel (Fig.
1, lanes 2 and 6). This result suggests that the HIV-1
promoter may contain more than one binding site for NC.
In DNase I footprinting analysis, we found that NC binds
to LTR in six regions. Previous studies have shown that
zinc-finger proteins have multiple binding sites on one
promoter and have the ability to bind in a sequence-
specific fashion to a wide variety of promoters derived
from the different species (Dynan and Tjian, 1983a,b,
FIG. 3. Competition analysis of HIV-1 NC binding to the HIV-1 pro-
moter. S, V, and b represent the cold self-probe, envelope V3 DNA, and
human b-globin DNA, respectively. The labeled double-stranded HIV-1
TR fragment extending from 2134 to 1155 (probe 2) was incubated
ithout NC (lane 1), with 0.75 mg of NC (lane 2), with 0.75 mg of NC, and
he unlabeled self fragment (probe 2) at a 300-, 900-, and 2,700-fold
olar excess over labeled probe 2 (lanes 3–5); or with 0.75 mg of NC
and the unlabeled HIV-1 V3 fragment at a 300- and 2,700-fold molar
excess over labeled probe 2 (lanes 6 and 7); or with 0.75 mg of NC and
he unlabeled human b-globin DNA fragment at a 300- and 2,700-fold
olar excess over labeled probe 2 (lanes 8 and 9). Data show that the
nlabeled self-competitor inhibits the band shift but the unlabeled
IV-1 V3 and human b-globin DNA do not.
aa
1
b cleotid
254 ZHANG, SHARMA, AND CRUMPACKER1985; Gidoni et al., 1984, 1985; Jones et al., 1986; Hardy
nd Shenk, 1988; Shi et al., 1991). This is in contrast to
Tat, which binds to DNA nonspecifically and reacts with
FIG. 4. DNase 1 protection of HIV-1 LTR by NC examined with 39 end-lab
nd electrophoresed in sequence gel as described under Materials and
155). Data show that NC has multiple binding regions within HIV-1 LTR.
old, and cellular transcriptional factor binding sites are underlined. The nuTAR through cellular proteins (Frankel et al., 1988; Wei etal., 1998). Taken together, our results provide evidence to
show that NC has the ability to bind to the HIV-1 LTR
promoter. It has been previously reported that NC binds
R DNA fragments 1 and 2. The footprint reaction products were processed
s. (a) LTR fragment 1 (bp 2416 to 2112). (b) LTR fragment 2 (bp 2134 to
7 binding sites on 59 HIV-1 LTR. The binding sites of NCp7 are shown in
e positions are derived from published sequences of HIV-1 clone pNL4-3.eled LT
Method
(c) NCpspecifically to an HIV-1 riboprobe (Berkowitz et al., 1993),
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255ENHANCING HIV-1 LTR BASAL-LEVEL ACTIVITY BY HIV-1 NCp7indicating that NC selectively binds to HIV-1 genomic
RNA. To our knowledge, there have been no prior data to
clearly show that NC binds to the HIV-1 LTR promoter.
Enhancement of HIV-1 LTR basal-level activity by NC
in an RNA runoff system
We further investigated whether NC affects LTR-di-
rected gene expression in an in vitro transcription sys-
tem. The RNA runoff experiments with HeLa nuclear
extract were used in this study (Promega, Madison, WI).
The effect of NC on LTR basal-level transcription activity
was examined with a reporter plasmid, in which the
HIV-1 LTR was cloned upstream of the CAT gene (So-
droski et al., 1985; Lu et al., 1989), allowing the transcrip-
tion of an approximately 1,400-nucleotide (nt) RNA tran-
script.
The NC alone enhances LTR basal-level activity (Fig.
5). At concentrations of 50 and 100 ng, NC enhances
LTR-CAT mRNA transcription in an ascending fashion
(Fig. 5, lanes 2 and 3). The densitometer scanning of the
bands from lanes 2 and 3 are 0.63 and 1.91 (height AU),
respectively. A higher concentration (200 ng) of NC does
not further enhance HIV-1 LTR-directed gene expression
in this assay system, suggesting saturation of NC at that
concentration. A CMV DNA template is used as a posi-
tive control for the in vitro transcription system. A 1,200-nt
RNA transcript, representing an end-to-end transcription
from a CMV DNA template is also shown (Fig. 5, lane 6).
This 1,200-base transcript serves as another marker,
FIG. 5. Detection of LTR-CAT runoff transcripts induced by HIV-1 NC
in vitro. Runoff reactions are as described under Materials and Meth-
ods. The final concentration of NC in each reaction was 50 ng (lane 2),
100 ng (lane 3), and 200 ng (lane 4). The 1,200-nt end-to-end transcript
(upper band) and the 363-nt transcript (lower band) of CMV are shown
in lane 6. HaeIII fX174 DNA as a molecular weight marker is shown in
ane 1, and the reaction without NC is shown in lane 5. This autora-
iogram was exposed to gel for 48 h.showing that actually a full-size runoff transcript from wLTR-CAT is transcribed. The size of the CAT RNA is about
1,400 bases compared to the CMV RNA. It has also been
reported that the full-length transcripts, rather than pre-
maturely terminated RNAs, are synthesized from the
HIV-1 LTR in most cell-free transcription extracts (Jones
et al., 1988; Toohey and Jones, 1989).
To determine the specificity of NC effect on LTR, we
examined whether NC alone would enhance a 380-base
G-free cassette transcription directed by HIV-1 LTR and a
200-base G-free cassette transcription directed by ade-
novirus major late promoter. NC alone did enhance the
HIV-1 LTR-directed 380-base RNA transcription but not
the adenovirus major late promoter-directed 200-base
RNA transcription (data not shown).
Enhancement of LTR-directed gene transcription by
NC in cooperation with cellular transcription factors
To determine whether NC can react synergistically
with general transcriptional factors (GTFs) to induce LTR
activity, we examined the effect of NC in the presence of
GTFs in RNA runoff experiments. The results show that
NC cooperates with GTFs as well as with NF-kB to
enhance LTR-directed RNA transcription in vitro (Fig. 6).
The induction of LTR-directed gene transcription in the
presence of the transcription factors alone (Fig. 6, lanes
2–4) and in the presence of NC together (Fig. 6, lanes
5–7) are shown.
It has been previously shown that both Sp1 and NF-kB
activate HIV-1 LTR basal-level activity (Jones et al., 1986;
uh et al., 1989; Folks et al., 1989; Osborn et al., 1989;
oli et al., 1990; Parrott et al., 1991; Antoni et al., 1994;
cElhinny et al., 1995), but NF-kB binds to DNA in acti-
vated cells in which IkBs are dissociated from NF-kB.
Our experiments show that NC enhances LTR basal-
FIG. 6. Detection of LTR-CAT runoff transcripts induced by different
proteins in vitro. The final concentration of transcription factor added in
ach reaction was 1 gsu of NF-kB (lane 2), or 1 gsu of NF-kK with 50
ng of NC (lane 5); 1 fpu of Sp1 (lane 3), or 1 fpu of Sp1 with 50 ng of NC
(lane 6); 1 gsu of TFIIB (lane 4), or 1 gsu of TFIIB with 50 ng of NC (lane
7). The reactions without external transcription proteins are shown in
lanes 8 and 10. A 363-nt CMV transcript from CMV DNA control is
shown in lane 9. the HaeIII-cleaved fX174 DNA as the moleculareight marker is shown in lane 1.
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256 ZHANG, SHARMA, AND CRUMPACKERlevel activity with GTFs and NF-kB, indicating that NC
lays a role in regulation of LTR activity in both resting
nd activated cells.
The experimental results described earlier show that
C enhances HIV-1 LTR basal-level activity in coopera-
ion with cellular general transcriptional factors. To de-
ermine whether NC is able to increase RNA transcrip-
ion with GTFs on another promoter, we examined ade-
ovirus major late promoter in this assay system. The
denovirus major late promoter allows the transcription
f a 200-base RNA transcript lacking guanosine resi-
ues, and the HIV-1 LTR allows the transcription of a
80-base RNA transcript lacking guanosine residues.
hen the general transcription factors were added to the
FIG. 7. Detection of the G-free runoff transcripts induced by different
proteins in vitro. The final concentration of transcription factor added in
each reaction was the same as in Fig. 6. The 200-nt transcript from
adenoviral major late promoter is used as an internal control. The reaction
without NC (lane 1); with 50 and 100 ng of NC (lanes 2 and 3). The reaction
with 1 gsu of NF-kB or with 1 gsu of NF-kB and 50 ng of NC (lanes 4 and
5); with 1 fpu of Sp1 or with 1 fpu of Sp1 and 50 ng of NC (lanes 6 and 7);
with 1 gsu of TFIIB or with 1 gsu of TFIIB and 50 ng of NC (lanes 8 and 9).
A 363-nt CMV transcript from the CMV DNA control is shown in lane 10.
Data show that NC enhances NF-kB, Sp1, and TFIIB-induced transcription
n each condition, but does not significantly affect the expression of a
00-nt transcript, which serves as an internal control.
T
CAT Activity in Transfe
Plasmid pCiS2p7 (1 mg) pCiS2p7 (5 mg)
pCiS2 —
pTZIIICAT pTZIIICAT
CPM 20652.5 6 0.3 36197.5 6 0.1
Fold of CPM 1.6 2.9
Note. The data shown are representative of four independent assays
as used in each transfection (5 mg of pTZIIICAT per condition). Acyextraction CAT assay (Kingston and Sheen, 1995).ssay system, NC enhances NF-kB, Sp1, and TFIIB-in-
uced HIV-1 LTR-directed RNA transcription in a similar
attern as previously shown in Fig. 6 (Fig. 7). The RNA
ranscription directed by the adenovirus major late pro-
oter, however, is not significantly affected (Fig. 7). Tran-
cription from the LTR with NC plus cellular-transcription
actors (Fig. 7, lanes 5, 7, 9) was compared to the tran-
cription with cellular-transcription factors alone (Fig. 7,
anes 4, 6, 8). The densitometer readings (height AU) of
he bands are 4.83 for NC plus NF-kB, 3.15 for NC plus
Sp1, and 2.62 for NC plus TFIIB. The readings of the
bands for transcription factors alone are 1.92 for NF-kB,
.35 for Sp1, and 1.96 for TFIIB. Transcription of a G-less
ranscript directed by the adenovirus major late promoter
200-nt) is an internal control in each reaction. A 363-nt
ranscript of CMV control DNA is shown in Fig. 7, lane 10,
hich serves as a molecular weight marker, to show that
380- and a 200-nt G-free transcript runs above and
elow, respectively, in the gel.
nhancement of LTR-directed CAT activity in T
ymphocytes transfected with plasmids
ncoding HIV-1 nc or gag
The enhancement of LTR-directed gene expression in
human T lymphocytes by HIV-1 NC was examined with
phase-extraction CAT assays. Two sets of CAT and HIV-1
gag plasmids were used in this experiment. Consistent
with the in vitro assay data, HIV-1 NC enhances LTR-
directed CAT gene expression up to 2.9- to 3.4-fold in T
cells posttransfection (Tables 1 and 2). Vectors in the
absence of HIV-1 ncp7 or gag did not increase CAT
activity in these two transfection assays.
The enhancement in CAT activity resulted from the
presence of NC. As shown in Table 1, transfection of NC
plasmid (pCiS2/nc7) increases CAT activity 2.9-fold in
transfected cells. A similar increase of CAT activity (3.4-
fold) was observed in a transfection assay using plasmid
pUCgag (Table 2). This plasmid contains a full-length gag
gene encoding MA, CA (p24), p6 Gag proteins in addition
to Gag NCp7. The enhancement of CAT activity post-
transfection with NCp7 alone (pCiS2/nc7) or in the pres-
ence of Gag (pUCgag) was similar (2.9- and 3.4-fold,
Tables 1 and 2). This indicates that almost all of the
Cells with HIV-1 ncp7
pCiS2p7 (5 mg) — —
pCiS2 — pCiS2
— pTZIIICAT pTZIIICAT
280.3 6 0.4 12184.9 6 0.1 12581.3 6 0.2
— — 1.0
med. Each data point is a mean of triplicates. A total of 10 mg of DNA
hloramphenicol was measured in 15 mg of protein lysate with phaseABLE 1
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257ENHANCING HIV-1 LTR BASAL-LEVEL ACTIVITY BY HIV-1 NCp7ability of Gag to enhance CAT activity was the result of
NCp7, and NCp7 can enhance CAT activity whether
present alone or in the presence of other Gag proteins.
Both transfection experiments with either HIV-1 ncp7 or
gag result in an increase in CAT activity, demonstrating
that NC enhances HIV-1 LTR basal-level activity, and this
may play a role in the HIV-1 replication cycle.
Mutations in nc zinc-finger domains reduce the
enhancement activity of integrated LTR-CAT
To examine whether the enhancement activity can be
affected by the mutations in NC, we employed transfec-
tion with HIV-1 proviruses, which contain mutations in nc
zinc-finger domain and analyzed the enhancement activ-
ity in human T-cell lines in which HIV-1 LTR is integrated
into the cellular genome. Three nc mutants were used in
this study: (1) pNC1/1 contains amino acid rearrange-
ments of zinc-finger sequences as duplications of the
first zinc-finger sequences; (2) pNC2/2 contains amino
acid rearrangements of zinc-finger sequences as dupli-
cations of the second zinc-finger sequences; and (3)
pNC2/1 contains the reversal of these sequences
(Gorelick et al., 1993). We examined these mutants in two
human T-cell lines. Human T-cell lines H938 and M311
contain stably integrated, silent copies of HIV-1 LTR
promoter linked to the CAT gene. Using this assay sys-
tem, we examined the activity of NC on HIV-1 LTR, which
was stably integrated into the cellular genome and in
chromatin structure. The viral promoter was in an au-
thentic chromatin context, a condition closely similar to
HIV-1 infection.
In both H938 and M311 cells, the provirus with wild-
type nc enhanced LTR basal-level activity by 34- and
fivefold compared to mock transfection, respectively, and
the three mutants containing zinc-finger mutations all
demonstrated decreased enhancement activity (Figs. 8a
and 8b). Mutant pNC2/1, containing a reversed zinc-
finger domain and 10–amino acid substitution, had the
T
CAT Activity in Transfe
Plasmid pUCgag (1 mg) pUCgag (5 mg)
pUC19 —
pC15CAT pC15CAT
24 (ng/ml) 0.002 0.005
CPM 2874.5 6 0.2 9776.5 6 0.1
Fold of CPM 1.0 3.4
Note. The data shown are representative of six independent assays
was the same as in Table 1. The p24 antigen levels were determined i
p24 antigen ELISA kit following the manufacturer’s instructions.
a ND 5 not done.
b Background value according to Dupont NEN p24 antigen assay prleast enhancement activity following transfection.DISCUSSION
In this study, we have demonstrated that NC binds to
HIV-1 LTR and enhances LTR basal-level transcription
cooperatively with general transcription factors in vitro.
The expression of CAT activity in transiently transfected
cells and in LTR stably integrated cells, following trans-
fection with nc or nc mutants, shows that NC enhances
LTR gene expression in human T lymphocytes, demon-
strating a biological role of NC on LTR activity in vivo.
his study of HIV-1 LTR basal-level activity differs from
tudies of cellular promoter basal-level transcription,
here the formation of the initiation complex (the basal-
evel activity) is regulated by activators. The basal-level
ranscription of a cellular gene, therefore, is purely an
perational term defined by the in vitro studies (Or-
hanides et al., 1996). In HIV-1 infection, the Tat-regu-
ated LTR activity is termed the activated level and the
re-Tat is termed the basal level (Feinberg et al., 1991;
essler and Mathews, 1991; Cullen, 1993; Lu et al., 1993;
dams et al., 1994; Moses et al., 1994). The basal-level
ctivity of HIV-1 LTR is not purely an operational term,
ecause these two levels of transcription occur sequen-
ially in the HIV-1 replication cycle. Other studies have
hown that the LTR basal-level activity is a prerequisite
f Tat-induced LTR activity, and Tat mRNA and TAR ele-
ent are transcribed by the basal activity (Kim et al.,
989; Feinberg et al., 1991; Kessler and Mathews, 1991;
lotman et al., 1991; Sakaguchi et al., 1991; Cullen, 1993;
dams et al., 1994; Michael et al., 1994; Alcami et al.,
995; Miller et al., 1997; Xiao et al., 1997). Our data show
hat NCp7 enhances LTR basal level activity with GTF
nd NF-kB, suggesting that NC plays a role in initiation of
HIV-1 transcription by recruiting GTF to the HIV-1 pro-
moter. This recruitment is part of the strategy to carry out
the role that allows HIV-1 to compete for RNA polymer-
ase II and GTF with cellular promoters to express HIV-1
early, spliced mRNA (Kim et al., 1989; Feinberg et al.,
1991; Kessler and Mathews, 1991; Klotman et al., 1991;
Cells with HIV-1 gag
pUCgag (5 mg) — —
pUC19 — pUC19
— pC15CAT pC15CAT
0.006 NDa 0.001b
331.0 6 0.6 2812.3 6 0.1 2851.3 6 0.3
— — 1.0
ed and each data point is a mean of triplicates. The assay condition
upernatant of cell lysate containing 15 mg of protein with Dupont NENABLE 2
cted T
perform
n the sSakaguchi et al., 1991; Cullen, 1993; Adams et al., 1994;
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258 ZHANG, SHARMA, AND CRUMPACKERMichael et al., 1994; Moses et al., 1994; Alcami et al.,
995; Xiao et al., 1997).
The footprinting analysis showed that NC binds to six
regions within HIV-1 LTR. The regions of the HIV-1 LTR
where the NC binds reveal the presence of some com-
mon sequences, particularly GAG. Two binding regions,
which overlap with the two Sp1 binding sites, reveal
nucleotide sequences of GACT and GGAGT, and in the
region of NC binding (2221 to 2229), which overlaps
with the region where cellular transcription factor NFAT-1
binds, also reveals the sequence GGATGGAG. Another
region of NC binding reveals sequences of GAGAAGT.
The binding region near the TATA box reveals a se-
uence of GCCCTCA (238 to 244) and, if the two nucle-
tides immediately adjacent are included, the sequence
s GAGCCCTCA (238 to 246). Thus, the sequences GAG
r GAXT are included in all of the identified regions of NC
inding or immediately adjacent to these binding re-
ions. This suggests sequence-binding specificity, and
inding to a region containing the TATA box.
Experiments are underway employing site-specific
utagenesis to determine the full significance of NC
inding regions on HIV-1 LTR. A possibility that NC binds
o LTR by a conformational feature is not excluded. In
omparison to Sp1, which binds LTR and activates pro-
oter basal-level activity, our data show that NC binds to
TR and enhances LTR basal-level activity. This en-
ancement cooperates with the activities of cellular tran-
FIG. 8. Mutations in the nc zinc finger domain reduce enhancement a
cells. The CAT activities (CPM) are from cell lysates, which were norma
The non-NC plasmid transfection and mock transfection are normalized
of p24. The data shown are representative of three independent assay
6 0.1); nc mutant pNC1/1 (column 2, SD 6 0.8); pNC2/2 (column 3, SD
nd mock transfection (column 6, SD 6 1.7). (b) HIV-1 nc mutants show
he same as for a. WT type (column 1, SD 6 1.7); nc mutant pNC1/1 (c
.9); non-NC plasmid (column 5, SD 6 0.7); and mock transfection (cocription factors, including Sp1, NF-kB, and to a lesser begree with TFIIB. To initiate its gene expression, HIV-1
TR has to compete with numerous cellular promoters
or a common but limited GTF pool. Our observations
ndicate that NC acts as a nucleation protein in HIV-1
nfection. The binding of NC to HIV-1 LTR may play an
mportant role in recruiting GTFs to the viral promoter,
nabling HIV-1 to rapidly replicate in resting cells by
utcompeting the surrounding cellular promoters for the
ommon GTF pool.
The synergistic enhancement of the promoter basal-
evel activity by transcription factors has been intensively
tudied by several groups (Blair et al., 1996; Kim and
aniatis, 1997; Wathelet et al., 1998). Synergistic en-
ancement of promoter activity is often observed in the
rocess of transcription initiation. The least-modest lev-
ls of transcription initiation may require a threshold
evel of activation domain synergy, and the degree to
hich transcriptional processivity is enhanced depends
n the quantity of activation modules targeted to the
romoter DNA, rather than the quality (Blair et al., 1996).
athelet et al. (1998) and Kim and Maniatis (1997) re-
orted a different mechanism on the coordinate activa-
ion of multiple transcriptional activators and their highly
ooperative assembly into a transcriptional complex.
hey showed that in induced transcription resulting from
virus infection, the interferon-b (IFN-b) promoter is
urned on by a virus-activated factor (VAF). The transcrip-
ional synergy occurs when VAF cooperatively assem-
(a) HIV-1 nc mutants show reduced LTR–CAT gene expression in H938
contain an equivalent amount of HIV p24 (400 pg, the internal control).
the maximum amount of lysate, which would be equivalent to 400 pg
rmed. Each data point is a mean of duplicates. WT type (column 1, SD
; pNC2/1 (column 4, SD 6 0.5); non-NC plasmid (column 5, SD 6 0.7);
d LTR–CAT gene expression in M311 cells. The assay procedure was
2, SD 6 1.6); pNC2/2 (column 3, SD 6 1.3); pNC2/1 (column 4, SD 6
, SD 6 1.8).ctivity.
lized to
to use
s perfo
6 0.1)
reduce
olumnles into the initiation complex by protein–protein inter-
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259ENHANCING HIV-1 LTR BASAL-LEVEL ACTIVITY BY HIV-1 NCp7action, since VAF only weakly binds to IFN-b promoter
(Kim and Maniatis, 1997; Wathelet et al., 1998). Our data
show that HIV-1 NC binds to HIV-1 LTR and cooperatively
enhances NF-kB, Sp1, and TFIIB activity in the cell-free
ystem. These data suggest that NC acts more like a
raditional DNA binding protein and facilitates the recruit-
ent of general transcriptional factors to the viral pro-
oter. The in vivo data also show that NC enhances
TR-CAT activity in T lymphocytes, although by threefold.
In the transient transfection experiments, we exam-
ned two sets of LTR-CAT/NC expression plasmids and
bserved a threefold increase of CAT activity in human T
ymphocytes. Expression of a partial or an entire Gag
ithout Rev has been seen in other Gag-expression
lasmids (Gottlinger et al., 1989; Berkowitz et al., 1993; Li
t al., 1993; Moldeveanu et al., 1995). In addition, similar
nhancing activities have been observed by others while
tudying promoter enhancement. Courey et al. (1989)
eported a three- to fourfold enhancement in activation of
SVtk promoter by Sp1 in SL2 cell. Verdin et al. (1990)
eported that a nuclease-hypersensitive site (nt 4481 to
982) in the pol gene of HIV-1 had a transcription-en-
ancing activity. This intragenic-hypersensitive region in-
reased 59 LTR-directed gene expression in U937 and
EM cells (two- to threefold), but not in T-lymphoid and
onocyte/macrophage cell lines (Verdin et al., 1990; Voln
int et al., 1994). The plasmid pUCgag does not contain
he pol gene and the transfection experiments were done
n T-lymphoid cells in our study. Therefore, the influence
f pol intragenic enhancer on CAT activity can be ex-
cluded from our results. The CAT activity measured from
T lymphocytes reflected the effect of gag (NC) on LTR
activity in these experiments. Furthermore, others have
demonstrated that transient transfections may not al-
ways accurately reflect in vivo regulation (Paludan et al.,
1989; Bresnick et al., 1990) because in the HIV-1-infected
cells, HIV-1 LTR is integrated into the cell genome and
packed into the chromatin structure. To determine the
effect of NC in this situation, we employed cells in which
the LTR is stably integrated into the cellular genome, and
transfected these cells with HIV-1 proviruses, which con-
tain mutations in nc zinc-finger domains. Our data show
that wild-type NC indeed enhances HIV-1 LTR basal-level
activity more than each of the mutants, indicating that NC
plays a similar role in HIV-1 infection.
Recent discoveries on the replication rate of HIV-1 in
vivo (Pantaleo et al., 1993a,b; Coffin, 1995; Ho et al., 1995;
ei et al., 1995; Perelson et al., 1996) add a new chal-
enge to studies of HIV-1 LTR basal-level activity, since
IV-1 rapidly replicates in peripheral blood mononuclear
ells (PMBC) as well as in nondividing cells. A Tat-
ndependent transcription has been reported in several
ypes of cells (Gendelman et al., 1989; Harrich et al.,
990; Mellors et al., 1991; De Mareuil et al., 1995; Luznik
t al., 1995), and data from other studies suggest that
at-independent transcription results from LTR basal-evel activity enhanced by viral proteins in the absence of oat (Harrich et al., 1990; Sakaguchi et al., 1991; Berkhout
nd Jeang, 1992; Alcami et al., 1995; De Mareuil et al.,
1995; Luznik et al., 1995; Madore and Cullen, 1995).
Several research groups have also reported that many
Gag mutants including nucleocapsid mutants, which
show a normal phenotype at late stage, were defective at
an early phase of replication (Reicin et al., 1995;
Kawamura et al., 1997). In addition, NC has been found in
the nucleus at an early stage of the infection and is
critical for the completion of proviral DNA synthesis (Gei-
genmuller and Linial, 1996; Schwartz et al., 1997; Tan-
hou et al., 1998). Our results indicate that HIV-1 Gag NC
lays an important role in regulation of LTR basal-level
ctivity. The effect of NC on regulation of HIV-1 promoter
asal-level activity may provide a target for control of the
IV-1 activation in nondividing cells.
MATERIALS AND METHODS
Plasmids. The HIV long terminal repeat (LTR) in vitro
ranscription templates were kind gifts of Drs. Sodroski
nd Perkins. The HIV-1 LTR-CAT plasmid pTZIIICAT con-
ains the XhoI–BamHI fragment of HIV-1 LTR-CAT gene
rom the plasmid pU3RIII, and the fragment was inserted
nto the SalI–BamHI sites of pTZ19U (Sodroski et al.,
985; Lu et al., 1989). Plasmid pHIV380 contains an
approximately 730-bp XhoI–HindIII Klenow-treated frag-
ment from a HIV–chloramphenicol acetyltransferase
(CAT) construct. The fragment was ligated into the SacI
site of the p(C2AT)19 G-free cassette vector (Duckett et
al., 1993). The adenovirus major late plasmid pML200 is
a derivative of vector pML(C2AT)19 with a shorter G-free
cassette (Maire et al., 1989). HIV-1 provirus plasmid
NL4-3 was obtained from Dr. Martin through the NIH
IDS Research and Reference Reagent Program and
sed as a template in synthesis of the DNA probes for
rotein–DNA binding analysis. Plasmid pUCgag is a re-
ombinant plasmid with gag fragment of pNL4-3 inserted
nto pUC19. The 59 LTR and the entire gag gene (1.5 kb)
f pNL4-3 were amplified with primers (59-TCCATCTA-
ATGGAAGGGCTAATTTGGTCC-39, 59-GCAGGAATTC-
TTCTGTCAATGGCCATTGT-39) by polymerase chain re-
ction (PCR). The amplified LTR-gag fragments were
igested with EcoRI and XbaI and inserted into the
olylinker region of pUC19. The generated recombinant
lasmid was named as pUCgag and the sequence was
onfirmed by DNA sequencing. The expression of gag
ene in pUCgag was driven by its natural promoter HIV-1
TR. Plasmid pSiC2p7 was a gift from Dr. Gottlinger
Strack and Gottlinger, 1998) and this plasmid expresses
IV-1 NCp7 in eukaryotic cells. HIV-1 LTR-CAT plasmid
TZIIICAT was as described earlier (Sodroski et al., 1985;
u et al., 1989) and pC15-CAT was from NIH AIDS Re-
earch and Reference Reagent Program (Josephs, 1995).
he HIV-1 NC zinc-finger mutants pNC1/1, pNC2/2,
NC2/1, and wild-type (Gorelick et al., 1993) were gener-
us gifts from Dr. Gorelick.
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260 ZHANG, SHARMA, AND CRUMPACKERProteins and transcription factors. HIV-1 NCp7 and p24
are purified proteins expressed in E. coli, provided by the
NIH AIDS Research and Reference Reagent Program
(Steimer et al., 1986; South et al., 1990; Lam et al., 1994).
ecombinant human NF-kB (p49), Sp1, and TFIIB were
btained from Promega.
Gel mobility shift assay. DNA probes were prepared by
CR amplification using 59 LTR of pNL4-3 as a template
Adachi et al., 1986): Primer A, 59-CCT TGATCTGTGGATC-
ACC-39, primer B, 59-AAGCTCGATGTCAGCAGTCT-39,
rimer C, 59-AAGGGTCTGAGGGATCTCTA-39, and primer
, 59-AGACTGCTGACATCGAGCTT-39. The double-
tranded LTR promoter fragments, probes 1 and 2, were
05 and 290 bp long, respectively, extending from bp
416 to 2112 and 2134 to 1155 on the 59 LTR of HIV-1.
he cold probes (competitors) were synthesized by PCR,
sing pNL4-3 as a template for V3 loop. The 59 and 39
rimers were as follows: 59-ATAAGCTTGCAGTCTAGC-
GAAGAAGA-39, 59-ATGAATTCTGGGTCCCCCTCCTGA-
GA-39. Human b-globin gene was amplified using the
genomic DNA of human peripheral blood mononuclear
cells as the template, with primer GH 20, 59-GAAGAGC-
CAAGGACAGGTAC-39, and primer GH 21, 59-GGAAAATA-
GACCAATAGGCAG-39 (Saiki et al., 1988). The amplified
fragments were analyzed by nucleotide sequencing and
found to be identical with the published genomic se-
quences.
The fragments were labeled by nick translation with
[a-32P]dCTP and DNA polymerase I. The nuclear extracts
ere prepared from CPT-K5 cells with a modified method
f Roeder and coworkers (Dignam et al., 1983); CPT-K5 is
a T-cell line carrying a topoisomerase I (topo-1) mutation
(Andoh et al., 1987; Zhang et al., 1997). The binding
reaction was adapted from the method contributed by
Chodosh (1998). Briefly, 1 mg of purified protein, 2 fmol of
32P-labeled DNA probe, 2 mg of double-stranded poly-
dl-dC), and 6 mg of BSA were in the reaction mixture.
he final reaction volume was 20 ml, and the mixture was
ncubated in 30°C for 45 min. The mobility shift was
nalyzed on 10% TBE polyacrylamide gel.
The competitive binding assay was performed accord-
ng to the mobility shift DNA-binding assay previously
mployed in studying zinc-finger protein (Hardy and
henk, 1988; Chang et al., 1989; Shi et al., 1991). The
self-competitor LTR probe 2, V3 loop fragment, and b-glo-
in fragment were 290, 319, and 408 bp, respectively. The
ompetitors were in a range of 300- to 2,700-fold molar
xcess over labeled probe 2, added simultaneously with
he protein (0.75 mg of NCp7), and hot-labeled probe.
DNase I footprint analysis. The DNase I footprint anal-
ysis followed a modified protocol of Brenowitz et al.
(1998). Probe DNAs were labeled at the 39 end, accord-
ng to the previously described protocol (Tabor et al.,
997). LTR probe 1 was labeled selectively at BspE1 site
ith [a-32P]dCTP and [a-32P]dGTP and LTR probe 2 was
labeled at HinfI site with [a-32P]dCTP, [a-32P]dATP, and
32[a- P]TTP by using the Klenow fragment of DNA poly-erase. Labeled DNA probes were gel-purified and
luted from Sepharose Cl-6B columns. The binding con-
itions were the same as in the band-shift assay, except
he final reaction volume was 50 ml and without poly-
dl-dC). The reaction products were purified by phenol-
hloroform, phenol-chloroform-isoamyl alcohol extrac-
ion, followed by ethanol precipitation, and were ana-
yzed on 6% polyacrylamide sequencing gel containing
.5 M urea.
RNA runoff analyses. For transcription reactions, we
mployed a protocol adapted from Nabel and coworkers
Duckett et al., 1993) and Promega (1995). A 25-ml reac-
tion volume contained 0.4 mM of rATP, rCTP, rGTP, and
0.016 mM of UTP; 1 ml of [a-32P]UTP (3,000 Ci/mmol); 3
M MgCl2; 100 ng of LTR-CAT plasmid, or 100 ng of
TR-G-free cassette plasmid with 100 ng of pML200, or
00 ng of CMV DNA control fragment. To determine the
ffect of NCp7 and cellular-transcriptional factors on
NA transcription, 50 ng of NCp7, 1 fpu of Sp1, and 1 gsu
f TFIIB or NF-kB was used per reaction. These assay
proteins and 8 units of nuclear extract were incubated at
30°C for 60 min. The runoff experiments using pHIV380
and pML200 were performed in the same way, except
the sample mixtures were incubated at 30°C for 30 min.
The approximately 380-bp G-less transcripts by LTR and
the approximately 200-bp G-less transcripts by adenovi-
rus major late promoter were recovered after RNase
treatment (Duckett et al., 1993; Schmid et al., 1991).
Nase T1 (150 U; Boehringer-Mannheim, Indianapolis,
N) was added, and samples were incubated for a further
5 min. RNA was recovered by phenol-chloroform extrac-
ion, followed by ethanol precipitation and resolved on
olyacrylamide TBE (5%)–urea gel. Dried gels were ex-
osed to Kodak BIOMAX MR film at 270°C with inten-
ifying screens.
Molecular weight markers for the gel electrophoresis
ere prepared from fX174 RF DNA HaeIII digest with
59-end labeling by [g-32P]dATP (3,000 Ci/mmol). When
preparing this marker to illustrate the size of our RNA
runoff transcripts, the resolution limit of 5% TBE–urea gel
(50–2,000 nt fragments) as well as the stability of mark-
ers were considered.
Cells. The RPMI 8402 cell line, a human T-lymphatic
leukemia cell line, was a gift from Dr. Andoh (Andoh et
al., 1987). H938 and M311 cells were from NIH AIDS
Research and Reference Reagent Program, and these
cells contain stably integrated, silent copies of the HIV-1
LTR promoter linked to the CAT gene. Cells were cul-
tured in growth media (RPMI 1640 90%, FBS 10%, peni-
cillin 100 U/ml, and streptomycin 100 mg/ml). The cells in
log-growth phase were used in the experiments.
Transient transfection and CAT assay. The test plas-
mids were mixed with log-growth cells at 10 mg of plas-
id per 3 3 106 cells in 300 ml culture media without fetal
bovine serum (FBS). Electroporation was done using
gene pulser electroprotocol with modification (Boss,
1990). Briefly, the transfection mix was incubated in a
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261ENHANCING HIV-1 LTR BASAL-LEVEL ACTIVITY BY HIV-1 NCp70.4-cm cuvette on ice for 5 min before and after trans-
fection. Electroporation was performed in a 0.4-cm cu-
vette, at 0.25 kV, 960 mF. After electroporation, the cells
ere cultured for 48 h in growth media. Cells were
arvested and lysates were titrated for protein concen-
ration with Pierce BCA assay. Where full-length HIV-1
T and NC mutant clones were employed in transfection
xperiments, the internal control for the effectivenesss of
ransfection was the amount of HIV p24 antigen pro-
uced (Gorelick et al., 1993). CAT activity was determined
y phase-extraction CAT assay, following the previously
ublished protocol (Kingston and Sheen, 1995).
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